Please assess the completion status of the following clinical trial:

Trial Title: Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults~* ADHD diagnosis (any type: Combined, Predominantly Inattentive, or Predominantly Hyperactive-Impulsive)~* Patients with an Adult ADHD Investigator Symptom Rating Scale (AISRS) score greater than 24 at screening/baseline~* Ability to read and understand English~Exclusion Criteria:~* Any significant history of cardiovascular disease or cardiovascular disease detectable via ECG~* History of diagnosis of substance or alcohol dependence or admission/hospitalization for rehabilitation for dependence~* Current neurologic or psychiatric diagnosis that would make patient inappropriate for participation~* Anxiety assessments of moderate or severe~* Depression assessments of moderate or severe~* History or current suicidal thoughts or attempts~* Known allergies, hypersensitivity, or intolerance to OROS MPH

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): OROS MPH Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
- 002 (Type: PLACEBO_COMPARATOR): Placebo Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).